Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medication Outcome in ECT-Resistant Depression.

Baruch Shapira1, Seth Kindler, Bernard Lerer

  • 1Jerusalem Mental Health Center, Ezrath Nashim Hospital, Jerusalem, Israel.

Convulsive Therapy
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration.

Acta neuropsychiatrica·2026
Same author

In Memoriam: Professor Dan J. Stein (1962-2025) - A Global Pioneer with an African Heart.

The international journal of neuropsychopharmacology·2025
Same author

Reply to Gattuso et al.: "Comments on 'Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming' by Brownstien et al. (2024)".

Molecular psychiatry·2025
Same author

DIO3 depletion attenuates ovarian cancer growth via reduced glycolysis and alterations in glutamine metabolism.

Molecular metabolism·2025
Same author

Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration.

Translational psychiatry·2025
Same author

Premorbid characteristics of the SAPAP3 mouse model of obsessive-compulsive disorder: behavior, neuroplasticity, and psilocybin treatment.

The international journal of neuropsychopharmacology·2025
Same journal

Wilson's disease, psychosis, and ECT.

Convulsive therapy·1998
Same journal

Maintenance electroconvulsive therapy for Parkinson's disease.

Convulsive therapy·1998
Same journal

Multiple ECT late in the course of neuroleptic malignant syndrome.

Convulsive therapy·1998
Same journal

Prejudice against ECT: competition with psychological philosophies as a contribution to its stigma.

Convulsive therapy·1998
Same journal

Quantifying utilization and practice variation of electroconvulsive therapy.

Convulsive therapy·1998
Same journal

Electroconvulsive therapy consultation: an update.

Convulsive therapy·1998
See all related articles

Electroconvulsive therapy (ECT)-resistant depression patients achieved full remission with antidepressant medication. This suggests electroconvulsive therapy may enhance subsequent antidepressant treatment effectiveness in refractory cases.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Electroconvulsive therapy (ECT) is a treatment for severe depression.
  • Some patients remain resistant or only partially respond to ECT.
  • The efficacy of subsequent antidepressant pharmacotherapy in these cases is under investigation.

Purpose of the Study:

  • To evaluate the effectiveness of antidepressant treatment in patients with ECT-resistant depression.
  • To identify specific antidepressant medications and augmentation strategies associated with remission.

Main Methods:

  • Retrospective analysis of 12 patients with ECT-resistant or partial-response depression.
  • Assessment of remission rates following antidepressant medication post-ECT.
  • Analysis of specific antidepressant agents (clomipramine, maprotiline, imipramine) and augmentation (lithium carbonate, haloperidol).

Related Experiment Videos

Main Results:

  • All 12 patients achieved complete remission within 2.2 months of antidepressant treatment.
  • Seven patients responded to clomipramine, one to maprotiline.
  • Four patients refractory to tricyclic antidepressants alone achieved remission with lithium augmentation.

Conclusions:

  • Antidepressant medication is effective in achieving remission in ECT-resistant depression.
  • Clomipramine and lithium augmentation show promise in managing refractory depression.
  • ECT may potentially increase sensitivity to subsequent antidepressant treatments.